Pulmocide
Biotechnology · Health Care
$85.5Mtotal raised · 3 rounds on record
$52Mlatest round · Venture round · Dec 2022 · 3 yr ago
2backers · Jeito Capital, SR One
200+team · employees, estimated range
Overview
Pulmocide is a biotechnology company developing novel inhaled medicines for pulmonary aspergillosis and other hard-to-treat respiratory diseases.
Funding and backers
Total raised
$85.5M
3 rounds on record
Latest round
$52M
Venture round · Dec 2022 · 3 yr ago
Team
201-500
employees, estimated range
Backers
2
Jeito Capital, SR One
The money's age
Long since its last round
47 months since the last round · not hiring
Momentum
0/100
no fresh signals
Last sign of life
1 mo ago
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Dec 6, 2022
Raised a round Venture round $52M
Dec 21, 2021
Raised a round Venture round $3.5M
Mar 19, 2017
Raised a round Venture round $30M · pharmaphorum
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Venture round | Dec 2022 | $52M | — | pulmocide.com |
| Venture round | Dec 2021 | $3.5M | — | pulmocide.com |
| Venture round | Mar 2017 | $30M | — | pharmaphorum |
Backed byfrom the funds' portfolios and accelerator catalogs
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Celestial Therapeutics is developing novel therapies based on innovative and groundbreaking science to treat, prevent and cure infectious…
Arrowsmith Inc. is a research-driven biotech focused on bringing next-generation phage therapy into clinical use for patients suffering…
Our Mission and Innovation We are a biotechnology pioneer dedicated to solving one of the greatest challenges in modern medicine: the…
Leyden Labs helps people live freely by developing products that protect from known and new respiratory viruses.
SpyBiotech is a clinical stage biotechnology company with novel vaccine platform technologies to target infectious diseases, cancer and…
DEVELOPING INHALED THERAPEUTICS IN RESPIRATORY DISEASES. Kinaset is developing KN-002 to treat all patients with severe asthma regardless…
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
Jeito CapitalVia a fund
SR OneVia a fund
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
News
Pulmocide Announces Termination of Opera-T Phase 3 Study with Opelconazole
Decision made after reviewing results of interim analysisLONDON, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Pulmocide Ltd., (
Read more
Report
Pulmocide Announces Termination of Opera-T Phase 3 Study with Opelconazole
Decision made after reviewing results of interim analysis LONDON - January 7, 2026 - Pulmocide Ltd., ("the Company"), a late-stage biopharmaceutical company developing the investigational product, inhaled opelconazole, for patients suffering from serious
Read more
Report
Pulmocide announces termination of Phase 3 study - Company Announcement - FT.com
The latest company information, including net asset values, performance, holding & sectors weighting, changes in voting rights, and directors and dealings.
Read more
Report
Pulmocide calls curtains on phase 3 antifungal trial over low response, higher mortality rate
Read more
Report
Successful treatment of an allergic bronchopulmonary aspergillosis patient with inhaled antifungal opelconazole
Read more
Report
Pulmocide Announces Presentation at 43rd Annual J.P. Morgan Healthcare Conference
LONDON - January 10, 2025 - Pulmocide Ltd., ("the Company") a late-stage biopharmaceutical company developing inhaled opelconazole for patients suffering from serious acute and chronic respiratory diseases, today announced that Dan Burgess, Chief Executiv
Read more
Report
Pulmocide Announces Successful Results from the OPERA-S Study: a Phase 2 Safety Study with Inhaled Opelconazole
Inhaled opelconazole observed to be generally well tolerated in this study as prophylaxis against pulmonary aspergillosis in lung transplant patients Discontinuations due to drug-related adverse events and drug-drug interactions lower in the opelconazole
Read more
Report
Pulmocide Announces Successful Results from the OPERA-S Study: a Phase 2 Safety Study with Inhaled Opelconazole
Inhaled opelconazole observed to be generally well tolerated in this study as prophylaxis against pulmonary aspergillosis in lung transplant patients Discontinuations due to drug-related adverse events and drug-drug interactions lower in the opelconazole
Read more
Report
Pulmocide Announces Presentation at 42nd Annual J.P. Morgan Healthcare Conference
LONDON, Jan. 03, 2024 (GLOBE NEWSWIRE) - Pulmocide Ltd., ("the Company") a late-stage biopharmaceutical company developing opelconazole for patients suffering from serious acute and chronic respiratory diseases, today announced that Dan Burgess, Chairman
Read more
Report
Pulmocide Announces New Clinical Data Confirming Low Potential for Drug-Drug Interactions with Inhaled Opelconazole
LONDON - October 16, 2023 - Pulmocide Ltd., ("the Company") a late-stage biopharmaceutical company developing novel inhaled therapies for patients suffering from serious acute and chronic respiratory diseases, today announced new clinical drug-drug intera
Read more
Report
Show more news